Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

doi:10.1038/ncomms11815

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Nature communications - 10 Jun 2016

Chabon Jacob J, Simmons Andrew D, Lovejoy Alexander F, Esfahani Mohammad S, Newman Aaron M, Haringsma Henry J, Kurtz David M, Stehr Henning, Scherer Florian, Karlovich Chris A, Harding Thomas C, Durkin Kathleen A, Otterson Gregory A, Purcell W Thomas, Camidge D Ross, Goldman Jonathan W, Sequist Lecia V, Piotrowska Zofia, Wakelee Heather A, Neal Joel W, Alizadeh Ash A, Diehn Maximilian

Abstract excerpt

Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib. We observe multiple resistance mechanisms in 46% of patients after treatment with first-line inhibitors,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Crizotinib

Share to Gene Amplification

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27283993
DOI: 10.1038/ncomms11815
PMCID: PMC4906406

Genes

EGFR
MET
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.PMID 27283993Read ↗

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.Semantic proximity Read ↗

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR InhibitorSemantic proximity Read ↗

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.Semantic proximity Read ↗

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.Semantic proximity Read ↗

Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.Semantic proximity Read ↗

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcomeSemantic proximity Read ↗

Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.Semantic proximity Read ↗

Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.Semantic proximity Read ↗

Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.